A 125 mg Solu-Medrol (methylprednisolone sodium succinate) dose bills as J2919 × 25 — J2919 is defined at 5 mg per unit, not per mg, and not on the older 40 mg or 125 mg codes some cheat sheets still show. The administration code follows how it was given: a slow IV push is 96374; an intramuscular injection is 96372; an infusion of 16 minutes or more (typical for 500 mg and above) is 96365. Given as a premedication before a chemo or biologic infusion, Solu-Medrol is neither of the visit’s initial codes — it’s the add-on 96375, reported once for each additional pushed drug.
Methylprednisolone sodium succinate is a corticosteroid, not an antineoplastic, so it never bills through the 96401-96549 chemotherapy family regardless of why it’s being given — CareCost Estimate’s Solu-Medrol reference flags this explicitly because billing 96413 on a Solu-Medrol line is one of the most common errors on oncology premed claims. The administration code instead follows the route and the documented time, the same as any other non-chemo drug in the 96360-96379 family:
| How it was given | Code |
|---|---|
| Slow IV push, the drug’s own administration and nothing else on the claim | 96374 |
| Intramuscular injection | 96372 |
| IV infusion, 16 minutes or more documented (typical for 500 mg and up) | 96365 (+96366 for additional hours) |
| Pushed as an additional drug after another initial administration (chemo or non-chemo) | 96375 |
A push and an infusion are distinguished by the minutes actually charted, not by the dose in the syringe — a 125 mg dose given as a genuine slow push over several minutes is 96374; the same 125 mg run in over 20 minutes with documented start and stop times is 96365. Higher doses (500 mg, 1 g) are far more often infused, which is why the drug’s hero copy on this site describes 96365 for the larger MS-pulse and transplant-rejection doses and 96374 for the smaller premedication doses — but the minutes on the chart are what actually control the code, not the mg in the vial.
HCPCS retired the old methylprednisolone sodium succinate codes — J2920 (up to 40 mg) and J2930 (up to 125 mg) — effective March 31, 2024, and consolidated billing into J2919 at 5 mg per unit, effective April 1, 2024. A claim line still carrying J2920 or J2930 denies today as an invalid, deleted code, which is exactly the trap in cheat sheets and old superbills that never got updated. The unit math is mg ÷ 5:
| Dose | J2919 units |
|---|---|
| 40 mg | 8 |
| 125 mg | 25 |
| 1 g | 200 |
The Medically Unlikely Edit for J2919 is 5,400 units per date of service on the practitioner table (MAI 3, Date of Service Edit: Clinical) — 27,000 mg, generous enough to cover the highest labeled pulse-dose regimens without tripping the edit on a legitimate claim.
NCCI limits an encounter to one initial administration code, and Solu-Medrol pushed ahead of another drug’s infusion almost never gets to be it:
“CPT codes 96360, 96365, 96374, 96409, and 96413 describe ‘initial’ service codes. For a patient encounter, only one ‘initial’ service code may be reported unless it is medically reasonable and necessary that the drug or substance administrations occur at separate intravenous access sites. To report 2 different ‘initial’ service codes, use National Correct Coding Initiative (NCCI) Procedure-to-Procedure (PTP)-associated modifiers.” — NCCI Ch. XI §B.2
Push Solu-Medrol ahead of a chemotherapy infusion and the chemo drug’s 96413 is the visit’s initial code; the steroid push is 96375, an add-on, not a second 96374. Push it ahead of a non-chemo biologic infusion — an infliximab or similar drug billed on 96365 — and the same logic applies: 96365 is the initial code, and the Solu-Medrol push is still 96375, because the hierarchy cares about which administration is first and highest-ranked on the encounter, not which drug is the “main event” clinically. 96374 only survives as the code when Solu-Medrol’s push is the sole or first administration of the day.
The 125 mg Act-O-Vial is labeled a single-dose container, so the JW/JZ labeling test applies to it — even though J2919 itself is not on CMS’s JW/JZ Modifier Policy HCPCS Codes list, so the claim edit that rejects a missing modifier is not enforced on this code. A fully administered 125 mg dose — nothing held back, nothing discarded — still carries modifier JZ on the J2919 line, attesting that zero drug was discarded. A partial dose drawn from a larger single-dose vial (500 mg, 1 g, 2 g) and not fully used reports the discarded remainder on its own line with JW; per Pub. 100-04 Ch. 17 §40, once a JW line exists, the line for the amount actually administered carries no modifier at all, not JZ and not JW. Neither modifier applies if the vial pulled is a multiple-dose container.
Solu-Medrol’s indication list is broad, and payers deny on a diagnosis that just says “steroid administration.” Code the condition being treated: G35.A–G35.D by MS type (G35.D if unspecified) for an MS exacerbation, J45.x (severity-specific) for an asthma exacerbation, J44.1 for a COPD exacerbation, T86.x (organ-specific, e.g. T86.11 kidney, T86.21 heart) for transplant rejection, and, when the push is treating a drug reaction rather than premedicating against one, T88.6XXA plus the specific T36–T50 adverse-effect code for the drug that caused it, or T78.2XXA (anaphylactic shock, unspecified) when the triggering agent isn’t identified. A premedication dose ahead of a chemo or biologic infusion is coded to the condition the infusion itself is treating, not to a generic steroid code.
Priced lines for the standalone push, Medicare basis, are in the Code this visit tool on the IV push page.
The administration code depends on how it was given: 96374 for a slow IV push (the visit’s only or first administration), 96372 for an intramuscular injection, or 96375 if it was pushed as an additional drug after another infusion’s initial code. The drug itself is J2919 × 25, since J2919 bills at 5 mg per unit.
Those codes were deleted effective March 31, 2024, when HCPCS consolidated methylprednisolone sodium succinate billing into J2919 (effective April 1, 2024) at 5 mg per unit. A claim line carrying J2920 or J2930 now denies as an invalid code. Update the superbill to J2919 and recalculate units as mg ÷ 5 rather than reusing the old per-40-mg or per-125-mg unit counts.
No. Solu-Medrol is a corticosteroid, not chemotherapy, regardless of the clinical context. The chemo drug takes 96413 as the encounter’s initial code; the Solu-Medrol premedication push is reported as the add-on 96375, not as a second 96413 or as 96374.
There is no single correct code — it depends on why the steroid was given: G35.A–G35.D by MS type (G35.D if unspecified) for an MS exacerbation, J45.x for asthma, J44.1 for COPD, T86.x for transplant rejection, or T88.6XXA plus the T36–T50 adverse-effect code for a drug reaction (T78.2XXA if the agent is unknown). A premedication dose is coded to the condition the following infusion is treating, not to a generic steroid-administration code.
Quoted passages are reproduced from the cited federal publications; everything else is our reading of them. The methodology by which we resolve source disagreements is described in the Methodology.